AstraZeneca Outlines Two-year Development, Debt Reduction Strategy
This article was originally published in The Pink Sheet Daily
Anglo-Swiss pharma reports first quarter sales increases for Seroquel and Crestor; Nexium declines.
You may also be interested in...
Deal demonstrates strength of AstraZeneca’s patents, analyst says.
Firm looks to expand $4 billion franchise into lucrative MDD market.
Firm bids to expand $4 billion franchise into bipolar disorder’s manic and depressive episodes, as patent challenges loom.